Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Neoplasm, Residual × abemaciclib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 25 Endometrial Neoplasms 6 Neoplasms 5 Neoplasm Metastasis 5 Triple Negative Breast Neoplasms 4 Ovarian Neoplasms 4 Prostatic Neoplasms 3 Head and Neck Neoplasms 3 Glioblastoma 3 Squamous Cell Carcinoma of Head and Neck 2 Sarcoma 2 Pancreatic Neoplasms 2 Lymphoma, Non-Hodgkin 2 Brain Neoplasms 2 Urologic Neoplasms 1 Thyroid Neoplasms 1 Thyroid Carcinoma, Anaplastic 1 Small Cell Lung Carcinoma 1 Sarcoma, Ewing 1 Retinoblastoma 1 Recurrence 1 Pathologic Complete Response 1 Osteosarcoma 1 Oligodendroglioma 1 Neoplasms, Squamous Cell 1 Neoplasm, Residual 1 Multiple Myeloma 1 Metastatic Castration-Resistant Prostate Cancer 1 Mesothelioma, Malignant 1 Meningioma 1

Interventions

blinatumomab 7 Cyclophosphamide 6 Rituximab 5 Lenalidomide 5 Dexamethasone 5 fludarabine 4 Azacitidine 4 venetoclax 3 fludarabine phosphate 3 Cytarabine 3 thymoglobulin 2 obinutuzumab 2 daratumumab 2 Whole-Body Irradiation 2 N,N-dicyclohexyl-isoborneol-10-sulfonamide 2 Methotrexate 2 Melphalan 2 Immunotherapy 2 Imatinib Mesylate 2 Clofarabine 2 Cladribine 2 Calcium Dobesilate 2 Busulfan 2 treosulfan 1 trastuzumab deruxtecan 1 tislelizumab 1 tisagenlecleucel 1 talquetamab 1 selinexor 1 sargramostim 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05708235 2026-03-05

MiRaDoR

MedSIR

Phase 2 Recruiting

Breast Neoplasms, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡